These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21913872)

  • 1. Genetic association studies in drug-induced liver injury.
    Daly AK; Day CP
    Drug Metab Rev; 2012 Feb; 44(1):116-26. PubMed ID: 21913872
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-induced liver injury: past, present and future.
    Daly AK
    Pharmacogenomics; 2010 May; 11(5):607-11. PubMed ID: 20415545
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic basis of drug-induced liver injury: present and future.
    Urban TJ; Daly AK; Aithal GP
    Semin Liver Dis; 2014 May; 34(2):123-33. PubMed ID: 24879978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatitis.
    Huang YS; Chern HD; Su WJ; Wu JC; Lai SL; Yang SY; Chang FY; Lee SD
    Hepatology; 2002 Apr; 35(4):883-9. PubMed ID: 11915035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetic association studies in drug-induced liver injury.
    Daly AK; Day CP
    Semin Liver Dis; 2009 Nov; 29(4):400-11. PubMed ID: 19826974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanisms of isoniazid-induced idiosyncratic liver injury: emerging role of mitochondrial stress.
    Boelsterli UA; Lee KK
    J Gastroenterol Hepatol; 2014 Apr; 29(4):678-87. PubMed ID: 24783247
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Susceptibility of N-acetyltransferase 2 slow acetylators to antituberculosis drug-induced liver injury: a meta-analysis.
    Shi J; Xie M; Wang J; Xu Y; Liu X
    Pharmacogenomics; 2015 Dec; 16(18):2083-97. PubMed ID: 26616266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of N-acetyltransferase 2 and cytochrome P450 2E1 gene polymorphisms with antituberculosis drug-induced hepatotoxicity in Western India.
    Gupta VH; Amarapurkar DN; Singh M; Sasi P; Joshi JM; Baijal R; Ramegowda PH; Amarapurkar AD; Joshi K; Wangikar PP
    J Gastroenterol Hepatol; 2013 Aug; 28(8):1368-74. PubMed ID: 23875638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The association between HLA-DQB1 polymorphism and antituberculosis drug-induced liver injury: a Case-Control Study.
    Chen R; Zhang Y; Tang S; Lv X; Wu S; Sun F; Xia Y; Zhan SY
    J Clin Pharm Ther; 2015 Feb; 40(1):110-5. PubMed ID: 25250564
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymorphism of the N-acetyltransferase 2 gene as a susceptibility risk factor for antituberculosis drug-induced hepatotoxicity in Tunisian patients with tuberculosis.
    Ben Mahmoud L; Ghozzi H; Kamoun A; Hakim A; Hachicha H; Hammami S; Sahnoun Z; Zalila N; Makni H; Zeghal K
    Pathol Biol (Paris); 2012 Oct; 60(5):324-30. PubMed ID: 21856096
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are Polymorphisms in Genes Relevant to Drug Disposition Predictors of Susceptibility to Drug-Induced Liver Injury?
    Daly AK
    Pharm Res; 2017 Aug; 34(8):1564-1569. PubMed ID: 28028769
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic Risk Factors in Drug-Induced Liver Injury Due to Isoniazid-Containing Antituberculosis Drug Regimens.
    Nicoletti P; Devarbhavi H; Goel A; Venkatesan R; Eapen CE; Grove JI; Zafer S; Bjornsson E; Lucena MI; Andrade RJ; Pirmohamed M; Wadelius M; Larrey D; Maitland-van der Zee AH; Ibanez L; Watkins PB; Daly AK; Aithal GP
    Clin Pharmacol Ther; 2021 Apr; 109(4):1125-1135. PubMed ID: 33135175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver injury caused by drugs: an update.
    Stirnimann G; Kessebohm K; Lauterburg B
    Swiss Med Wkly; 2010; 140():w13080. PubMed ID: 20927685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Human leukocyte antigen genetic risk factors of drug-induced liver toxicology.
    Grove JI; Aithal GP
    Expert Opin Drug Metab Toxicol; 2015 Mar; 11(3):395-409. PubMed ID: 25491399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NAT2 polymorphisms and susceptibility to anti-tuberculosis drug-induced liver injury: a meta-analysis.
    Wang PY; Xie SY; Hao Q; Zhang C; Jiang BF
    Int J Tuberc Lung Dis; 2012 May; 16(5):589-95. PubMed ID: 22409928
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using genome-wide association studies to identify genes important in serious adverse drug reactions.
    Daly AK
    Annu Rev Pharmacol Toxicol; 2012; 52():21-35. PubMed ID: 21819236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. N-acetyltransferase and cytochrome P450 2E1 gene polymorphisms and susceptibility to antituberculosis drug hepatotoxicity in an Indian population.
    Mishra S; Daschakraborty S; Shukla P; Kapoor P; Aggarwal R
    Natl Med J India; 2013; 26(5):260-5. PubMed ID: 25017831
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NAT2 and CYP2E1 polymorphisms and susceptibility to first-line anti-tuberculosis drug-induced hepatitis.
    Lee SW; Chung LS; Huang HH; Chuang TY; Liou YH; Wu LS
    Int J Tuberc Lung Dis; 2010 May; 14(5):622-6. PubMed ID: 20392357
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The NAT2 tag SNP rs1495741 correlates with the susceptibility of antituberculosis drug-induced hepatotoxicity.
    Ho HT; Wang TH; Hsiong CH; Perng WC; Wang NC; Huang TY; Jong YJ; Lu PL; Hu OY
    Pharmacogenet Genomics; 2013 Apr; 23(4):200-7. PubMed ID: 23407048
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variations of NAT2 and CYP2E1 and isoniazid hepatotoxicity in a diverse population.
    Leiro-Fernandez V; Valverde D; Vázquez-Gallardo R; Constenla L; Fernández-Villar A
    Pharmacogenomics; 2010 Sep; 11(9):1205-6; author reply 1207-8. PubMed ID: 20860460
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.